Bifogade filer
Last day of trading in warrants series TO 3 in Immunovia
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Today, 11 April 2025, is the last day of trading in warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company"). Subscription of shares by exercise of warrants series TO 3 is ongoing until 15 April 2025. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.24 per share.
Immunovia carried out a rights issue of units during August – September 2024 (the “Rights Issue”). Each unit issued in the Rights Issue consisted of two (2) shares, two (2) warrants series TO 2 and one (1) warrant series TO 3. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company. Today, 11 April 2025, is the last day of trading in warrants series TO 3.
Complete terms and conditions for the warrants are available on the Company's website, www.immunovia.com.
Summarized terms for warrants series TO 3:
- Structure: One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company.
- Exercise period: 1 April 2025 – 15 April 2025.
- Subscription price: SEK 0.24 per share.
- Issue volume: 62,211,989 warrants series TO 3. Upon full exercise, 62,211,989 shares will be issued and the Company will receive approximately SEK 14.9 million before issue costs.
- Last day of trading in warrants of series TO 3: 11 April 2025.
- Share capital and dilution: Upon full exercise of all 62,211,989 warrants series TO 3, the share capital will increase by a maximum of SEK 1,866,359.67 to SEK 9,723,625.56 through the issuance of a maximum of 62,211,989 new shares, resulting in that the total number of outstanding shares in the Company will increase from 261,908,863 to 324,120,852. Upon full exercise of all warrants series TO 3, the dilution amounts to approximately 19.2 percent.
- Outcome and delivery of new ordinary shares: The outcome of the exercise of warrants will be published via a press release on or around 17 April 2025. Shares that have been subscribed and paid for may be registered on the subscriber’s securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Immunovia.
Please note that the warrants series TO 3 that are not exercised by 15 April 2025, or sold by 11 April 2025, will expire without value. In order for the warrants not to lose their value, active subscription of shares or sale of warrants is required. Please note that some nominees may close their application earlier than 15 April 2025.
Advisers
Vator Securities AB acts as financial adviser to Immunovia in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Immunovia in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.